Lumenis Showcases Its Dual Modality CO2 Laser Solution for Smart Tissue Management Providing Women With Better Options for Gynecology Health Problems
YOKNEAM, Israel, June 15, 2015 (GLOBE NEWSWIRE) -- Lumenis Ltd. (Nasdaq:LMNS), the world's largest energy-based medical device company for surgical, ophthalmology and aesthetic applications, is showcasing its portfolio of CO2 laser solutions for minimally invasive gynecological surgery at the 11th American Association of Gynecologic Laparoscopists (AAGL) International Congress, taking place June 16-19, 2015 in Jerusalem, Israel.
A photo accompanying this release is available at http://www.globenewswire.com/newsroom/prs/?pkgid=33729.
Lumenis' portfolio of laser systems, fibers and accessories is built on the principle that strong collaboration with the gynecology community energizes innovation and leads to better patient care.
The AcuPulse(TM) DUO is the only CO2 laser system that combines free beam and fiber technologies to treat a range of indications in gynecology, including endometriosis, adhesions and uterine fibroids. These gynecological conditions usually affect women during their reproductive years and are associated with pelvic pain and infertility, affecting normal sexual function and quality of life.1 The unique pulsed and continuous power and exposure mode settings of AcuPulse DUO enable optimal control over cutting, ablation and coagulation with the least amount of disturbance to adjacent tissue.
Smart tissue management is one of the main challenges in laparoscopic gynecological surgery needing to avoid perforations, adhesion formation and other potential complications when treating in close proximity to important intra-abdominal structures such as the bowel, bladder, ureter and major blood vessels.
Lumenis' broad range of advanced durable and flexible CO2 laser fibers enhance safety by providing a clear visible aiming beam that helps the surgeon target the tissue of interest, and are the only ones with a renewable tip for cost effective and user friendly operation. Along with a designated set of gynecological handpieces, they provide the thermal control and precision required for smart tissue management.
Lumenis encourages AAGL attendees to visit booth number 15 to experience the CO2 laser on a specially designated gynecological simulator in order to explore the benefits of the CO2 laser energy.
AAGL attendees are also welcome to attend a video session by Dr. Francisco Carmona, demonstrating the advantages of fiber use.
The session is entitled: "Adhesiolysis and Excision of Bladder Endometriosis using Lumenis AcuPulse CO2 Laser and FiberLase Flexible CO2 Laser Fiber," and will take place on Thursday, June 18 at 11:40 in Hall B.
"As a leading medical technology company headquartered in Israel, we are delighted that AAGL chose Jerusalem as the location for this important meeting," said Tzipi Ozer-Armon, CEO of Lumenis. "The meeting's slogan - 'where ancient history and innovative start-ups intertwine' - provides the perfect context to share our continued legacy of innovation with local healthcare professionals and international guests."
To learn more about Lumenis' CO2 laser solutions for gynecological surgery, please visit: https://vimeo.com/100938383.
Lumenis (Nasdaq:LMNS) is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For nearly 50 years, Lumenis' ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods. For more information visit: www.lumenis.com
Information provided in this press release may contain statements relating to current expectations, estimates, forecasts and projections about future events that are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include but are not limited to the Company's plans, objectives and expectations for future operations, including its projected results of operations. Forward-looking statements are often characterized by the use of forward-looking terminology such as "may," "will," "expect," "anticipate," "estimate," "continue," "believe," "should," "intend," "plan," "project" or other similar words, but are not the only way these statements are identified. These forward-looking statements are based upon our management's current estimates and projections of future results or trends. Actual results may differ materially from those projected as a result of certain risks and uncertainties, including those risks discussed under the heading "Risk Factors" in our most recent Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
1. Meuleman C. et al., Outcome after multidisciplinary CO2 laser laparoscopic excision of deep infiltrating colorectal endometriosis (2009), Reproductive BioMedicine Online ,Vol 18. No 2. pp. 282-289.
CONTACT: For further information: Mai Duong Lazar Partners Ltd. (646) 871-8492
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Lumenis Ltd. via Globenewswire